ABL Diagnostics (FR001400AHX6 – ABLD), a leading Euronext-listed company in the development of molecular biology assays and software for microbiology laboratories, has announced the official appointment of the company and its exclusive distributor, Laborama Co. Ltd., to provide Next Generation Sequencing (“NGS”) solutions to the National Laboratory for Public Health (NLPH) in Lithuania.
This partnership will last for two years and will focus on implementing NGS solutions for various microbiology applications, including HIV, SARS-CoV-2, Influenza A, Influenza B, and other pathogens. ABL Diagnostics and Laborama will work together to provide robust and innovative assays, library preparation reagents, and software solutions to NLPH.
As of 2023, the Next Generation Sequencing (NGS) market is estimated to be worth approximately $6.5 billion and is expected to grow at a rate of 13% per year, reaching $9.4 billion in 2026. The demand for NGS technology has significantly increased in clinical settings since the COVID-19 pandemic, with clinical trials and routine testing accounting for more than half of the market. The NGS reagents offered by ABL Diagnostics are crucial for this technology’s success.
Managing director of Laborama, Interlux Group company, Marius Savickas, expressed his excitement for the expanded partnership with NLPH, saying, “We are extremely pleased to keep supporting NLPH for implementing innovative NGS technologies. We started offering products for HIV genotyping for a couple of years now and are delighted to expand our partnership, with the help of ABL Diagnostics, to other relevant applications.”
Head of Diagnostics at ABL Diagnostics, Dimitri Gonzalez, also shared his enthusiasm for the partnership, stating, “ABL Diagnostics is working with more than 50 exclusive distributors on a worldwide basis, which includes a long-lasting partnership with Laborama in Lithuania. We are honored to help NLPH and to supply our latest NGS-based technologies, which shall help optimize the management of key diseases in the country for the next decades.”
The detailed terms of the agreement between ABL Diagnostics, Laborama, and NLPH have not been disclosed.
ABL Diagnostics is a public company listed on Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6) and offers a wide range of innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection and genotyping. These products have a significant presence in the microbiology market, with a primary focus on HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, and other viral and bacterial targets.
Laborama, a part of Interlux Group, specializes in providing innovative, top-quality technologies and solutions for medicine, science, and biotechnology industries. The company offers various supplies and training for researchers and users of advanced laboratory technologies, with a primary focus on flow cytometry, clinical and industrial microbiology, molecular biology, and cell biology solutions. Laborama also offers professional 24/7 technical support and maintenance for its products.
For more information about ABL Diagnostics and Laborama, please visit their respective websites at www.abldiagnostics.com and www.laborama.lt.
This press release contains forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions considered reasonable by ABL Diagnostics but are subject to numerous risks, including economic conditions, financial markets, and the markets in which ABL Diagnostics operates. The occurrence of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to differ materially from the forward-looking statements. This press release and the information contained herein do not constitute an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Distributed by https://pressat.co.uk/
